Cagrilintide Reference

Long-acting amylin analog · Phase 3 investigational

ClassLong-acting amylin analog
StatusPhase 3 investigational
Typical vials5 mg, 10 mg
Dose range0.25 mg to 2.4 mg
FrequencyOnce weekly
Half-life~7.5 days
Dosing unitmilligrams
RouteSubcutaneous injection

What Cagrilintide is

Cagrilintide is a long-acting amylin analog from Novo Nordisk. Amylin slows gastric emptying and promotes satiety through a different receptor family than GLP-1, which is why cagrilintide is most often studied and used alongside semaglutide as the CagriSema combination.

It is not FDA approved as a standalone. The escalation below is the Phase 2 monotherapy schedule; combination protocols typically run both compounds on the same weekly clock.

Reconstitution math

Concentration is everything: the same 5 mg vial gives a different draw for every amount of bacteriostatic water you add. The table uses the common 2 mL setup for each vial size, which puts every unit on a U-100 insulin syringe at 25 mcg for the default vial. Dashes mark draws too small to measure or larger than the syringe.

VialBAC waterConcentration0.25 mg0.5 mg1 mg1.7 mg2.4 mg
5 mg2 mL2.5 mg/mL10 u20 u40 u68 u96 u
10 mg2 mL5 mg/mL5 u10 u20 u34 u48 u
Cagrilintide syringe drawsDRAW GUIDEEach dose as a filled syringe5 mg vial + 2 mL bacteriostatic water = 0.25 mg per 0.1 mL (10 units).0102030405060708090100units on a U-100 insulin syringe0.25 mg10 u (0.1 mL)0.5 mg20 u (0.2 mL)1 mg40 u (0.4 mL)1.7 mg68 u (0.68 mL)2.4 mg96 u (0.96 mL)peprecon.com
Draw positions for the common doses at the default setup.

Dosing and protocol

Phase 2 monotherapy escalation, 0.25 to 2.4 mg weekly.

With the longest half-life in this library (about 7.5 days), cagrilintide accumulates for roughly five weeks before leveling off. If you model it in the Planner stacked with semaglutide, a same-day weekly schedule for both matches how the trials dosed the pair.

Cagrilintide titration scheduleDOSINGThe published escalation, step by stepDose per injection (weekly), from the schedule cited below.012mg159131721week0.250.511.72.4maintenancepeprecon.com
Each step is held before escalating; the final dose continues as maintenance.

Pharmacokinetics

Cagrilintide has published human pharmacokinetics: half-life about 7.5 days via a fatty di-acid albumin binder. The curves below are normalized one-compartment models built from the cited half-life, the same math the Planner uses. They show shape and timing, not absolute blood levels.

Cagrilintide single-dose curvePHARMACOKINETICSOne dose, start to finishRelative level after one subcutaneous dose. Half-life ~7.5 days; about 97% cleared by 39 days.0%25%50%75%100%0102030days after injectionpeak ~3 dayshalf of peakpeprecon.com
Cagrilintide accumulation with weekly dosingPHARMACOKINETICSThe same weekly dose builds for weeksRelative level with the same dose every week. Levels stop climbing around week 6.0%25%50%75%100%012345678weeks on the same weekly dosesteady statemarkers = weekly injectionspeprecon.com
Why week-one effects understate the eventual dose: levels build for weeks.

Storage and handling

Lyophilized vials keep best cold, dark, and dry; refrigeration is the community default and freezing lyophilized powder is common for long holds. After reconstitution, refrigerate at 2 to 8 C, do not freeze the solution, and date the vial. Bacteriostatic water's preservative keeps multi-dose use practical for about 28 days by USP convention, though our 120-day stability study found the preservative itself outlasts that window.

Got a certificate of analysis with your vial? Run it through our COA Reader: it reads the report in plain English, checks purity and mass against the label claim, and links the testing lab’s own verification page. Our guide to reading a COA explains what the numbers do and do not tell you.

Sources

  1. Lau et al., Once-weekly cagrilintide for weight management, Lancet 2021 (PMID 34798060)
  2. Frias et al., CagriSema in type 2 diabetes, Lancet 2023

Related references: Semaglutide · Tirzepatide